Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: Implication for vaccine development

9Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In light of the recent detection of BSE in North America and its endemic nature in other regions of the world, there is a real need to employ cell culture conditions that do not require any animal-derived material. Here we report the use of an ultra-low protein serum-free medium (VP-SFM, Invitrogen) for the amplification of poxviruses in primary chicken embryo fibroblasts (CEF). We compared the amplification of four different poxviruses (canarypox, modified Ankara Virus (MVA), vaccinia virus strain Copenhagen and myxoma strain Lausanne) in three different media: DMEM 10%, DMEM 2% and serum-free medium VP-SFM. VP-SFM is a serum-free, ultra-low protein medium containing no proteins or peptides of human or animal origin designed to support the replication of viruses and the production of recombinant proteins and monoclonal antibodies. Our results show that high titre poxvirus stocks can be prepared in VP-SFM equivalent to that prepared in serum containing medium. © Springer 2005.

Cite

CITATION STYLE

APA

Gilbert, P. A., Comanita, L., Barrett, J., Peters, A., Szabat, M., McFadden, G., & Dekaban, G. A. (2005). Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: Implication for vaccine development. Cytotechnology, 48(1–3), 79–88. https://doi.org/10.1007/s10616-005-3795-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free